Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

Weiss Ratings restated their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a research note published on Saturday,Weiss Ratings reports.

Several other research firms have also weighed in on FDMT. Royal Bank of Canada lowered their target price on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research report on Monday, January 13th. Leerink Partners decreased their target price on shares of 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Morgan Stanley lowered their price target on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a research report on Monday, January 13th. Finally, Bank of America decreased their price target on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $38.56.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT opened at $5.93 on Friday. The firm has a market capitalization of $274.14 million, a price-to-earnings ratio of -2.08 and a beta of 2.81. The business’s 50 day simple moving average is $5.97 and its 200-day simple moving average is $10.05. 4D Molecular Therapeutics has a 12 month low of $4.43 and a 12 month high of $36.25.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its position in shares of 4D Molecular Therapeutics by 5.3% during the 4th quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after purchasing an additional 3,675 shares during the period. Peapod Lane Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter valued at $806,000. Marquette Asset Management LLC acquired a new stake in 4D Molecular Therapeutics in the 4th quarter worth approximately $116,000. Barclays PLC grew its holdings in 4D Molecular Therapeutics by 141.0% in the 3rd quarter. Barclays PLC now owns 114,848 shares of the company’s stock valued at $1,241,000 after buying an additional 67,202 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd increased its stake in 4D Molecular Therapeutics by 81.3% during the third quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company’s stock valued at $265,000 after acquiring an additional 11,002 shares during the period. Institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.